Radiation boost may help stem cell transplants beat tough leukemia

NCT ID NCT03121014

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether adding targeted total marrow irradiation to standard chemotherapy before a stem cell transplant can help prevent relapse in people with high-risk acute myeloid leukemia or myelodysplastic syndromes. About 38 adults aged 18–65 will receive the combined treatment. The main goal is to see if more patients survive one year without their cancer returning.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Fludarabine, Busulfan, ATG, Tacrolimus, and total marrow irradiation
What this could lead to
If successful, this could improve the chance of staying cancer-free after a stem cell transplant for people with hard-to-treat leukemia or myelodysplastic syndromes.
What could go wrong
This is a small, early-phase study (38 participants) with no control group. The intense treatment carries serious risks like infection, organ damage, and graft-versus-host disease. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Illinois at Chicago

    Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.